Eight members of the editorial board of a scientific journal have resigned after it published a slew of controversial papers that critics fear could be used for DNA profiling and persecution of ethnic minorities in China.
The journal, Molecular Genetics & Genomic Medicine, is the latest to be caught up in controversy involving ethically fraught research. Emails obtained by The Intercept show that the journals editor-in-chief has been slow to respond to queries about the papers, which involve research on Tibetans and Uyghurs, among other ethnic groups, and were first brought to her attention in March. The journal is published by Wiley, a multinational company based in New Jersey that is one of the worlds premier scientific publishers.
Studies involving DNA profiling, facial recognition, and organ transplantation have sparked controversy at other journals, but this is the first time that so many members of a journals editorial board eight of 25 have resigned in response to such issues.
Yves Moreau is seen at the Thermodynamics Instituteat the University of Leuven in Leuven, Belgium, on Feb. 4, 2020.
Photo: Lies Willaert
The papers were flagged by Yves Moreau, a bioinformatician at the University of Leuven in Belgium who over the past few years has waged a tireless campaign to get journals to retract troubling or unethical papers.
Moreaus quest began in 2015, when Kuwait announced plans for compulsory collection of DNA from all citizens, residents, and visitors. He helped spearhead an international campaign against the law and won an early victory when it was overturned the following year. He became convinced that if left unchecked, science and artificial intelligence would be used to further authoritarianism. In technology, we have this nice comfortable geek image, he said. But when you really look at the history of technology, you see that it has been a nexus of power forever for at least 2,000 years. While many geneticists have worked for decades to overturn the idea that race is a scientific concept, Moreausaw that authorities around the worldcould exploit new technologies like readily available DNA testing for political gain.
Moreau later turned his attention to DNA profiling in China, particularly in Xinjiang, where an estimated1 million Uyghurs and other ethnic minorities have been interned in camps or forced into labor. Authorities there have alsocollected DNA samples from residents. Moreau periodically runs an automated search for papers on ethically charged topics. Earlier this year, that search turned up 18 papers at Molecular Genetics & Genomic Medicine.
Some of the papers describe genetic differences between ethnic groups. Police can use such research for DNA profiling, to better match crime suspects with DNA samples from the broader population. Other papers relied on samples that Moreau suspected were taken without proper consent. The Chinese government has been collecting DNA from men of all ethnicities, with the aim of building out genetic information for all 700 million males in China. Chinese police also forcibly collect DNA from certain groups, including migrant workers and political dissidents.
While Molecular Genetics & Genomic Medicine isnt a leading outlet for genetic research, it has an impact factor of 2.183, meaning that its papers are cited and read by other scientists. The Wiley name lends it an imprimatur of respectability.
As its title suggests, the journal was founded to focus on genetics research with medical applications. Many of the editorial board members study how genetics can help doctors treat patients or help scientists cure disease. But in 2019, the journal started publishing papers by authors in China on forensic genetics, a field that involves close collaboration with police. Forensic genetics has long been controversial in the United States. It is even more problematic in China, where DNA collection is part of a sustained effort to persecute ethnic minorities and other groups.
The title of one paper published by the journal is Forensic characteristics and genetic affinity analyses of Xinjiang Mongolian group using a novel six fluorescent dye-labeled typing system including 41-Y-STRs and 3 Y-InDels. Another maps genetic differences between branches of Chinas majority ethnic group, Han Chinese, and other groups, including Tibetans and Hui Muslims. Several of the papers list co-authors or funding from institutions affiliated with Chinese police. One lists a co-author from the Public Security Bureau in Tibet, the police agency in the region.
A graphic published in the journalMolecular Genetics & Genomic Medicinepurports to represent the genetic distance between various ethnic groups, including Uyghur groups.
Credit: onlinelibrary.wiley.com
Hart replied the next day. I am looking into this matter and will respond shortly, she wrote. Moreau sent several follow-up emails. But months passed without an update, he told The Intercept.
On Tuesday, in response to questions from The Intercept, the Wiley public affairs office emailed a statement from Hart. We are actively investigating and driving toward a timely, transparent resolution, Hart said. We take the concerns expressed extremely seriously and regret that delayed communications may have indicated otherwise.
In June, Moreau took the issue to the entire editorial board. In a lengthy email, he listed the suspect papers and explained how police in China use forensic genetics.
Other board members echoed his calls for an investigation. Several said they were not actively involved in the journals work and had no idea that the papers had even been published. The journals editorial board positions are honorary; scientists often sit on multiple boards at once.
In emails obtained by The Intercept, Hart wrote to the board that same day, explaining that she had experienced adeath in her familyand had drafted a message to Moreau that ended up trapped in her outbox. I will send a message soon outlining our decision on how to address this issue, she wrote.
A few weeks later, when she had not provided any further explanation to the board or to Moreau, board members started resigning.
I would have wanted to hear much more quickly from the editorial staff, said Ophir Klein, a pediatric medical geneticist at the University of California San Francisco and one of the board members who quit. The lack of communication made me really concerned, he added.
The lack of communication made me really concerned.
Another board member, Joris Veltman, told The Intercept that he has remained on the board so that he can push for scrutiny of the papers. On July 7, Veltman, who is the dean of the Biosciences Institute at Newcastle University Medical School in the United Kingdom, escalated the issue by emailing Wileys management. The publishers director of research integrity, Chris Graf, responded that Wiley would begin an investigation immediately. Veltman asked why Wiley hadwaited so long.
In a statement, a Wiley spokesperson wrote that the companys Integrity in Publishing Group was overseeing the matter. We have completed the first step of the investigation, which is to assess concerns vis--vis our publishing standards, the statement read. We are now proceeding to connect with the authors and the institutional review boards associated with the papers to clarify the consent procedures for the research undertaken. The spokesperson said that the company could not provide a timeline for the investigation, beyond to say that it would likely continue into September.
Moreau said the focus on consent is too narrow. The larger question, he said, is whether the journal should be publishing research on vulnerable minorities, some of which directly involves the authorities persecuting them. Klein, the board member, said that if the research is determined to be unethical, at a minimum it should be retracted.
Moreau is not holding his breath. He has previously secured retractions from IEEE and Springer Nature, two other major scientific publishers, but Wiley has declined to retract a paper on ethnicity and facial recognition that he and others flagged in 2019. In September 2020, the journal, WIREs Data Mining and Knowledge Discovery, issued an expression of concern. The note focuses only on possible misrepresentation of a data set and figure in the article, not broader ethical issues.
Last month, The Guardian reported that the editor of another Wiley journal, Annals of Human Genetics, resigned in September 2020 after Wileydeclined to publish a letter he co-authored with Moreau and others proposing that his and other journals boycott papers from China. In turning down the letter, Wiley senior managers said that publishing it could cause problems for its China office, he told the paper.
Moreau said he will persist. At this point, you cannot stay silent, he told the Molecular Genetics & Genomic Medicine editorial board in one email. This situation is creating a shameful embarrassment that reflects poorly on all medical genetics journals and on the entire medical genetics community. Public trust in human genetics depends on our communitys ability to transparently abide by its moral duty.
View post:
Journal Board Members Resign After Controversial Papers - The Intercept - First Look Media
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022